Evidence map›Paper›PMID 35801203›Full record

ArticleFrontiers in medicine2022

In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study.

Meizi Kang, Jing Chen, Lingling Liu, Cheng Xue, Xiaojing Tang, Jiayi Lv, Lili Fu, Changlin Mei, Zhiguo Mao, Yawei Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Cardiovascular Biomarkers in Nocturnal Hemodialysis and Their Association With Physical Performance.Hemodialysis international. International Symposium on Home Hemodialysis · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Meizi KangDivision of Nephrology, The Second Affiliated Hospital of Nantong University, Nantong, China.
Jing ChenDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lingling LiuDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Cheng XueDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Xiaojing TangDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiayi LvDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lili FuDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Changlin MeiDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhiguo MaoDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yawei LiuDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Bing DaiDivision of Nephrology, Kidney Institute of People's Liberation Army of China, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Shanghai Changzheng Hospital · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor 23(FGF23) is the most important biomarker and pathogenic factor in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). In the moderate and severe stages of chronic renal failure, abnormally elevated circulating FGF23 can lead to some complications, including myocardial hypertrophy, which is positively correlated with all-cause mortality. However, the circulating FGF23 level of different hemodialysis modalities, the underlying essential regulatory factors, and potential clinical benefits remain to be elucidated. In this retrospective cohort study, 90 in-center nocturnal hemodialysis (INHD) and 90 matched conventional hemodialysis (CHD) patients were enrolled. The complete blood count, intact FGF23(iFGF23), calcium, phosphorus, PTH, and other biochemical and echocardiographic parameters of INHD and CHD patients were collected and analyzed at 1-year follow-up. The all-cause mortality was recorded during the 7-year follow-up. Furthermore, the regulatory factors of iFGF23 and its association with echocardiographic parameters and mortality were investigated by multivariate regression. The levels of iFGF23 and serum phosphate in patients undergoing INHD were significantly lower than those in patients undergoing CHD. The left ventricular volume index (LVMI) in patients with INHD was significantly attenuated and positively correlated with the drop of serum iFGF23. The INHD group had reduced all-cause mortality compared to the CHD group. Multivariate analysis showed that iFGF23 was positively correlated with serum calcium, serum phosphorus, and calcium-phosphate product. The calcium-phosphate product is an independent determining factor of serum iFGF23. Compared with the CHD group, the INHD group presented with a significantly reduced circulating iFGF23 level, which was closely associated with attenuation of left ventricular hypertrophy, but INHD reduced all-cause mortality in an FGF23 independent manner.

Indexed as

calcium-phosphate productChronic Kidney DiseaseMineral and Bone Disorder (CKD-MBD)fibroblast growth factor 23in-center nocturnal hemodialysisleft ventricular hypertrophy

Identifiers

PMID35801203
PMCPMC9253468
OpenAlexW4283273981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.